Researchers presented a study protocol for a trial evaluating the efficacy of 3 forms of virtual reality interventions for patients with highly prevalent chronic lower back pain.
The researchers collected real world data about the economic impact of using onabotulinumtoxinA to treat patients with chronic migraine in order to establish the drug’s complete treatment benefit.
The researchers created two new “swear” words and assessed the pain-relieving effects of saying these new words during an ice-water pain challenge.
Besides acetaminophen, NSAIDs, triptans, ergot alkaloids, and adjunct antiemetics, gepants and ditans are recently approved for migraine patients.
Investigators conducted the first the first double-blind, randomized, controlled trial evaluating the safety and efficacy of intravenous immunoglobulin vs placebo patients with idiopathic small fiber neuropathy.
Routine pain assessments using validated scales are vital to develop personalized management strategies, according to investigators.
Data analysis revealed that CGRP mAbs were discontinued more frequently than onabotulinumtoxinA (23% vs 3%).
While there are concerns about long-term prescribed opioid use among individuals with chronic noncancer pain, until now there hasn’t been a study which investigated whether the same patients engage in a risky pattern of use in the long term.
To help standardize peripheral nerve ultrasound protocols, study investigators pooled reference cross-sectional area values of lower extremity nerves.
Inexpensive, practical, and safe strategies to reduce patients’ pain level during inactivated PRP scalp injections are reviewed.
